- TLDR Biotech
- Archive
- Page 12
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | August 22 - 25, 2024
Tome Biosciences burns through $213M with nothing to show, Moderna's RSV vaccine lands European Commission approval, Eli Lilly leads the revenue pack in Q2, Novo Nordisk's Bio Innovation Hub partners with MBC BioLabs, Bayer to lay off 150 employees in Basel, Jazz Pharma seizure med misses Ph3 primary endpoint
Biotech & Pharma Updates | August 21 - 22, 2024
Versant Ventures and Novartis partner to launch Borealis Bioscience, updated COVID shots from Pfizer, BioNTech & Moderna get FDA approval, WuXi Biologics H1 2024 new projects grow but profits fall, Illumina Ventures looks to raise third fund at $300M, Eli Lilly expands antibody discovery pact with Oblique, Liquidia sues FDA over approval exclusivity clause, Tome Biosciences is struggling despite $200M+ raise, Vertex runs marketing foul according to UK's MHRA, Thailand ticks Asia's first new monkeypox strain infection
Biotech & Pharma Updates | August 20 - 21, 2024
GondolaBio launches with $300M and three BridgeBio assets, Retension Pharmaceuticals $10.4M Series A, Roche expands mpox PCR testing acces, Celaid and Tokyo Medical and Dental University stem cell R&D collab, Regeneron's myeloma bispecific rejected by FDA over manufacturing concerns, Windtree Therapeutics running low on cash, Aadi Bioscience decimates R&D department, biopharma execs embrace sustainability but significant hurdles exist, and Astellas employee indicted in China on espionage charges
Biotech & Pharma Updates | August 19 - 20, 2024
Eli Lilly's GIP/GLP-1 golden-goose reduces type 2 diabetes occurrence, J&J nabs FDA approval for first-line mAb+small molecule combo in lung cancer, Pathalys Pharma $105M Series B, Organon buys migraine med Emgality rights from Eli Lilly for multiple countries, Emergent to donate 50k smallpox vaccines, Ozempic/Wegovy use may be linked to suicidal thoughts, Teva & Biogen (separately) sued for alleged pharmacy/PBM kickbacks related to MS meds
Biotech & Pharma Updates | August 18 - 19, 2024
Walgreens and BARDA decentralized clinical trial partnership, BioNTech & MediLink ADC partial clinical hold lifted, MindBio reports positive LSD microdosing Ph2a data in depression, Avidity's $345M fundraise, TYK Medicines planned $74M HKEX IPO, Eli Lilly concludes Morphic takeover, Liquidia's tentative FDA approval collapses stock, and FDA med device recalls aren't really recalls
Biotech & Pharma Updates | August 15 - 18, 2024
AstraZeneca nabs Imfinzi perioperative lung cancer FDA approval, Novo Nordisk invests $221M in new raw materials site, Audax PE buys Avantor's CRO division while also selling healthcare consultancy to Blackstone, Gavi has $500M for mpox shot access, Pfizer & BioNTech's COVID-19/flu vaccine attempt falls short in Ph3, Genentech shutters separate cancer immunology research department
Biotech & Pharma Updates | August 14 - 15, 2024
Medicare reveals first drug price negotiations, Bavarian Nordic stock nearly doubles on mpox global health emergency concerns, Zealand Pharma searches for commercial partner for their obesity med, Abata (Treg) lands strategic investment from BMS, Bayer's restructuring (allegedly) ain't slowing down BD efforts, SIGA Tpoxx antiviral misses primary endpoint, the L's keep stacking for Lykos as they cut 75% of their staff
Biotech & Pharma Updates | August 13 - 14, 2024
Gilead snags accelerated approval for cholangitis med, Acelyrin posts positive Ph3 skin disorder data, Avidity's up to $300M public offering, Arrowhead wants to get in on obesity, Avenge Bio and Galera Therapeutics wind down, bluebird bio stocks sinks as sickle-cell gene therapy uptake moves at glacial pace, Grail and Evotec slash a combined 750 jobs, WHO declares mpox a public health emergency
Biotech & Pharma Updates | August 12 - 13, 2024
Eli Lilly opens glassy $700M Boston R&D site, Evotec handed $75M milestone from BMS, atai Life Science and Cybin want to succeed where Lykos has stumbled, Novartis heart failure generic suit fails (again), Actuate Therapeutics' underwhelming IPO, Prolific Machines nabs grant to biomanufacture mAbs for low- and middle-income countries, and Boundless Bio doesn't have boundless job openings
Biotech & Pharma Updates | August 11 - 12, 2024
J&J's talc lawsuit saga may be ending, Sandoz biosimilar approval signals fourth Eylea (Regenron) competitor, Pfizer lands immunocompromised RSV Ph3 win, Halda Therapeutics $126M Series B, $924M botox industry M&A, FibroGen to layoff 127 SF-based staffers, and there's a new "largest protein" in town
Biotech & Pharma Updates | August 8 - 11, 2024
ARS Pharmaceuticals nasal epinephrine spray FDA approved, Merck pays up to $1.3B for bispecific asset, Avidity posts positive Ph1/2 DMD data, Sandoz's Humira biosimilar keeps on making money, Cabaletta reports adverse event in CAR-T lupus trial, 23andMe tries to cash in on GLP-1 hype, and Lykos Therapeutics can't catch a break with 3 of their papers getting redacted
Biotech & Pharma Updates | August 7 - 8, 2024
Eli Lilly's stupendous Q2 results, AI-biotechs Recursion & Exscientia merge, Vertex's Casgevy reaches reimbursement deal with UK's NHS, Novartis' FDA accelerated approval for nephropathy med, Bavarian Nordic snag $150M+ BARDA contract, Sanofi's Ph3 myeloma win, Merck & Co.'s Ph3 lung cancer miss, and Sarepta's earnings disappoint investors